Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKesson
Moodys
McKinsey
Colorcon

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

PATANOL Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Patanol, and when can generic versions of Patanol launch?

Patanol is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in PATANOL is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Patanol

A generic version of PATANOL was launched as olopatadine hydrochloride by APOTEX INC on December 14th, 2019.

Drug patent expirations by year for PATANOL
Drug Prices for PATANOL

See drug prices for PATANOL

Drug Sales Revenue Trends for PATANOL

See drug sales revenues for PATANOL

Recent Clinical Trials for PATANOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ORA, Inc.Phase 2
Université de MontréalPhase 4
Michael Marchand, MDPhase 4

See all PATANOL clinical trials

Recent Litigation for PATANOL

Identify potential future generic entrants

District Court Litigation
Case NameDate
Alcon Manufacturing Ltd. v. Barr Laboratories Inc.2007-11-07
ALCON MANUFACTURING, LTD v. APOTEX INC.2006-11-15
ALCON RESEARCH, LTD. v. APOTEX INC.

See all PATANOL litigation

Pharmacology for PATANOL
Synonyms for PATANOL
(z)-11-(3-(dimethyl-amino)-propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
(Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid
[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid
[11-(3-Dimethylamino-propylidene)-6,11-dihydro-dibenzo[b,e]oxepin-2-yl]-acetic acid; hydrochloride
{(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
11-((Z)-3-(Dimethyl-amino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid
11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid
113806-05-6
140462-76-6
140462-76-6 (hydrochloride)
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid
806O056
AB00698500_11
AB00698500-07
AB00698500-09
AB00698500-10
AC1NQXZH
AKOS005557129
AKOS025149450
ALO-4943A
AM84372
AN-33374
API0005265
BCP12203
BDBM50002096
BIDD:GT0285
BRD-K37130586-003-01-3
BRD-K67637637-003-12-6
C07789
CHEBI:94593
CHEMBL1189432
CHEMBL1719
CS-0053963
D08293
D27V6190PM
DB00768
DTXSID3023390
FT-0082377
GTPL7249
HMS2089K10
JBIMVDZLSHOPLA-LSCVHKIXSA-N
KW-4679
KW-4943A
L000748
LS-172239
MLS006011811
MolPort-003-986-254
Olopatadin
Olopatadina
Olopatadine
Olopatadine (INN)
Olopatadine [INN:BAN]
OLOPATADINE HYDROCHLORIDE
Olopatadinum
Pazeo
SB10717
SCHEMBL4668
SMR004703490
SR-01000763388
SR-01000763388-3
STK624184
TL8000403
UNII-D27V6190PM
ZINC1850
Paragraph IV (Patent) Challenges for PATANOL
Tradename Dosage Ingredient NDA Submissiondate
PATANOL SOLUTION/DROPS;OPHTHALMIC olopatadine hydrochloride 020688 2006-07-17

US Patents and Regulatory Information for PATANOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PATANOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996   Start Trial   Start Trial
Novartis PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996   Start Trial   Start Trial
Novartis PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996   Start Trial   Start Trial
Novartis PATANOL olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Moodys
Merck
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.